Vemlidy (tenofovir alafenamide) / Gilead - LARVOL DELTA

Population health and epidemiologic trends in weight gain among people with HIV. (PubMed, Curr Opin HIV AIDS) - "Weight gain among PWH is heterogeneous and should be interpreted in the context of baseline nutritional status, ART exposure, and population setting. Future studies should identify which patterns of weight gain predict adverse clinical outcomes and evaluate interventions that reduce metabolic risk."

Journal • Cardiovascular • Diabetes • Dyslipidemia • Genetic Disorders • Human Immunodeficiency Virus • Hypertension • Infectious Disease • Metabolic Disorders • Obesity

The effect of tenofovir alafenamide fumarate on lipid profiles in pregnant women with hepatitis B virus. (PubMed, Eur J Gastroenterol Hepatol) - "TAF is effective in chronic HBV-infected pregnant women, but its lipid-elevating effect relative to TDF warrants clinical attention."

Journal • Dyslipidemia • Hepatitis B • Infectious Disease • Inflammation

Real-world effectiveness and safety of tenofovir amibufenamide in treatment-naïve chronic hepatitis B: a 48-week retrospective cohort study. (PubMed, Front Med (Lausanne)) - "Tenofovir amibufenamide (TMF) is a newly recommended first-line nucleos(t)ide analogues for chronic hepatitis B (CHB) in China. Because the study lacked a comparator group, these findings should be regarded as observational. Comparative conclusions about the safety or superiority of TMF relative to tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF) require dedicated head-to-head studies."

Journal • Real-world evidence • Retrospective data • Dyslipidemia • Hepatitis B • Infectious Disease • Inflammation

Antiretroviral therapy regimens initiated during pregnancy and risks of adverse perinatal outcomes. (PubMed, AIDS) - "Our observational study findings for the composite outcome were comparable to the IMPAACT 2010/VESTED trial in a real-world programmatic setting and enabled evaluation of additional regimen and broader set of outcomes. In settings where randomized trial data are limited, well designed observational emulations of trials using nonrandomized data can provide informative evidence. As Botswana expands use of TAF in pregnancy, these results provide reassuring evidence supporting its safety."

Adverse events • Journal • Human Immunodeficiency Virus • Infectious Disease • Small for Gestational Age

Pradefovir mesylate and tenofovir amibufenamide for chronic hepatitis B: a systematic review and pragmatic treatment algorithm. (PubMed, Front Pharmacol) - "Their clinical positioning relative to the guideline-endorsed benchmark tenofovir alafenamide (TAF) for chronic hepatitis B management remains undefined, particularly regarding renal/bone safety and drug-drug interaction profiles. TMF may represent an alternative to TAF for patients with renal/bone risk or anticipated long-term therapy, though definitive equivalence requires prospective head-to-head randomized trials. PDV offers comparable short-term efficacy to TDF, with longer-term data now available; continued follow-up will define its role among nucleotide prodrugs."

Journal • Review • Dyslipidemia • Hepatitis B • Infectious Disease • Inflammation • Metabolic Disorders • CYP3A4

Efficacy and Safety of Switching from Entecavir to Tenofovir Alafenamide for Chronic Hepatitis B Patients with Low-Level Viremia. (PubMed, Curr Med Sci) - "Switching to TAF may be beneficial for patients with LLV after prolonged ETV therapy, as it is associated with a significantly higher rate of CVR. No lipid metabolism-related disorders were observed following the switch to TAF."

Journal • Hepatitis B • Infectious Disease • Inflammation • Metabolic Disorders

Machine Learning Model for Predicting Hepatocellular Carcinoma Development in Patients With Hepatitis B Virus-Related Cirrhosis Receiving Antiviral Therapy. (PubMed, Kaohsiung J Med Sci) - "We included 1592 patients with HBV-related cirrhosis who had received entecavir, tenofovir disoproxil fumarate, or tenofovir alafenamide for at least 1 year. Risk stratification showed the 10-year incidences of HCC for the low-, intermediate-, and high-risk groups were 9%, 26%, and 67%, respectively. The proposed machine learning model for predicting development of HCC exhibited good predictive performance in patients with HBV-related cirrhosis undergoing NA therapy."

Journal • Fibrosis • Hepatitis B • Hepatocellular Cancer • Immunology • Infectious Disease • Oncology • Solid Tumor • AFP

Longitudinal Adherence Trajectories of First-Line Nucleotide Analogues among US Older Adults with Chronic Hepatitis B. (PubMed, Drugs Aging) - "Over half of older adults with CHB consistently adhered to NAs, with significant variation in adherence patterns across the individual NAs. Overall, TAF was less likely to be associated with declining adherence patterns than other NAs. Understanding these long-term adherence patterns can help in developing targeted interventions to improve CHB care in older adults."

Journal • Hepatitis B • Infectious Disease • Inflammation

Design and synthesis of tenofovir monophenyl ester phosphonoamidate prodrugs with improved anti-hepatitis B virus activity and intrahepatic tenofovir enrichment. (PubMed, Bioorg Chem) - "Tenofovir Alafenamide (TAF, formerly known as GS-7340, Fig...Under this framework, compound 3a1 demonstrated significantly enhanced intracellular TFV accumulation in PBMCs compared with TAF. Collectively, these results position 3a1 as a promising next-generation TFV prodrug with potential for improved efficacy and safety."

Journal • Hepatitis B • Infectious Disease • Inflammation

Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Response (clinicaltrials.gov) - P3 | N=930 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

New P3 trial • Hepatitis B • Infectious Disease • Inflammation

Weight trajectories in virally suppressed people with HIV compared to matched people without HIV, and predictors of weight gain: a 3-year cohort study from the US TRIO Healthcare Network. (PubMed, J Acquir Immune Defic Syndr) - "Weight change in suppressed PWH are similar to those of matched PWoH. Clinical and sociodemographic characteristics, not ART regimens, correlated with 3-year gain in VS PWH."

Journal • Genetic Disorders • Human Immunodeficiency Virus • Infectious Disease • Metabolic Disorders • Obesity

Safety and Efficacy of TAF to Prevent MTCT of HBV in Middle/Late Pregnancies With High HBV DNA Load (clinicaltrials.gov) - P=N/A | N=200 | Recruiting | Sponsor: Xingfei Pan | Trial completion date: Dec 2024 ➔ Dec 2026

Trial completion date • Hepatitis B • Infectious Disease • Inflammation

Reduced-frequency bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV: a single-centre randomised phase 2 pilot trial in Spain. (PubMed, EClinicalMedicine) - P4 | "Once-weekly dosing is not supported as a maintenance strategy; twice-weekly and three-times-weekly dosing require confirmation in larger, adequately powered studies with close virological monitoring before any clinical role can be considered. Instituto de Salud Carlos III and Institut d'Investigacions Biomèdiques August Pi i Sunyer."

Journal • P2 data • Hepatitis B • Human Immunodeficiency Virus • Infectious Disease • Inflammation • CD4

A Challenging Case of a Patient With Both Hepatic and Small Bowel GISTs: Metachronous or Metastatic? (ACG 2026) - "Case Description/ A 47-year-old Asian male with controlled chronic hepatitis B on tenofovir alafenamide were first noted to have a new 6.3 cm hepatic lesion during routine abdominal ultrasound...After a prolonged hospitalization, the patientâs health condition improved and has had no recurrent GIST after 2 years on imatinib 400 mg daily...Since primary hepatic eGIST is uncommon, extensive abdominal and pelvic imaging prior to tumor resection and rigorous postoperative surveillance are essential. Figure: MRI abdomen demonstrating a large segment 5/8 hepatic mass (9.1 Ã 10.9 cm) with T2 hyperintensity, peripheral progressive enhancement, central necrosis, and peripheral diffusion restriction, without vascular invasion."

Clinical • Metastases • Gastric Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • Gastrointestinal Stromal Tumor • Hepatitis B • Hepatocellular Cancer • Hepatology • Infectious Disease • Liver Cancer • Peritoneal Cancer • Sarcoma • Septic Shock • ANO1 • KIT

A Sharp Turn: Severe Acute Hepatitis B After Presumed Acupuncture Exposure (ACG 2026) - "She received tenofovir and 5 days of intravenous N-acetylcysteine, with transient improvement followed by worsening bilirubin and international normalized ratio...She continued tenofovir alafenamide...Mild hepatosplenomegaly. Figure: Edema of the duodenum and pancreatic head as well as right upper paracolic gutter."

Addiction (Opioid and Alcohol) • Beta-Thalassemia • CNS Disorders • Genetic Disorders • Hematological Disorders • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Liver Failure

Tenofovir Alafenamide for the Prevention of Hepatitis B Virus Reactivation in Cancer Patients Receiving Systemic Therapy: A Systematic Review (ACG 2026) - "Four studies, including two retrospective cohorts, one randomized trial, and one prospective cohort, were analyzed. Three studies investigated patients receiving chemotherapy, and one investigated patients receiving immunotherapy. Among 333 TAF-treated patients, HBV reactivation occurred in 4 patients, corresponding to a pooled proportion of 3.0% (95%CI 0.8%-11.2%), with moderate heterogeneity (I2=64.5%)."

Clinical • Review • Hepatitis B • Hepatology • Infectious Disease • Liver Failure • Oncology

CHAPAS-5: An Adaptive Platform Trial for Evaluation of Novel Treatment Regimens in Children and Adolescents With HIV in Africa (clinicaltrials.gov) - P3 | N=800 | Not yet recruiting | Sponsor: University College, London

New P3 trial • Human Immunodeficiency Virus • Infectious Disease

The impact of switching to tenofovir alafenamide on lipid profile and renal function in chronic hepatitis B: a retrospective cohort study. (PubMed, Eur J Gastroenterol Hepatol) - "Switching to TAF was associated with clinically meaningful increases in absolute lipid fractions without worsening atherogenic ratios or renal function. Nevertheless, a minority transitioned to higher cardiometabolic risk categories, supporting individualized lipid monitoring, particularly in younger patients and those with low baseline LDL or HDL."

Biomarker • Journal • Retrospective data • Chronic Kidney Disease • Diabetes • Dyslipidemia • Fibrosis • Hepatitis B • Immunology • Infectious Disease • Inflammation • Metabolic Disorders • Nephrology • Renal Disease

COMPARATIVE EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE VERSUS TENOFOVIR DISOPROXIL FUMARATE FOR PREVENTION OF MOTHER-TO-CHILD TRANSMISSION IN PREGNANT WOMEN WITH CHRONIC HEPATITIS B: A SYSTEMATIC REVIEW AND META-ANALYSIS (UEGW 2026) - No abstract available

Retrospective data • Review • Hepatitis B • Hepatology • Infectious Disease • Inflammation

Tenofovir Alafenamide Versus Entecavir as Switch Therapy After Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B. (PubMed, J Clin Med) - "Alanine aminotransferase normalization rates (83.0% vs. 78.8%; p = 0.575) and virological suppression rates (97.8% vs. 97.1%; p = 1.000) were similarly high in both groups. TAF and ETV demonstrated similar long-term renal safety and antiviral efficacy, supporting both agents as reasonable switch options for CHB patients requiring TDF discontinuation because of renal safety concerns."

Journal • Hepatitis B • Infectious Disease • Inflammation • Nephrology • Renal Disease

Same-day initiation of tenofovir alafenamide-based pre-exposure prophylaxis with drug-level feedback for transgender women in Uganda. (PubMed, AIDS) - P=N/A | "Oral F/TAF PrEP adherence among TGW in Uganda was low and not affected by drug-level feedback or tailored adherence counseling. Long-acting injectable PrEP formulations should be considered for this population."

Clinical • Journal • Human Immunodeficiency Virus • Infectious Disease

Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum (clinicaltrials.gov) - P=N/A | N=205 | Terminated | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Completed ➔ Terminated; The study was closed to accrual early based on Study Monitoring Committee review indicating that the study objectives had either been achieved or could not be met within a reasonable timeframe for the then-open arms.

Trial termination • Human Immunodeficiency Virus • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Never Too Late: A Case Report of Severe Fanconi Syndrome Developing After More than a Decade of Silent Tenofovir Disoproxil Fumarate Exposure. (PubMed, Reports (MDPI)) - "TDF was discontinued, and her antiretroviral regimen was modified to tenofovir alafenamide fumarate (TAF), emtricitabine (FTC), darunavir, and ritonavir, combined with vitamin D supplementation. Over a 6-month follow-up period, renal function normalized, electrolyte wasting resolved, and metabolic acidosis completely reversed. This case highlights that TDF-induced proximal tubulopathy can manifest even after a decade of uneventful therapy, particularly when co-administered with a boosted protease inhibitor."

Journal • Endocrine Disorders • Human Immunodeficiency Virus • Infectious Disease • Metabolic Disorders • Musculoskeletal Pain • Nephrology • Pain • Renal Disease • Secondary Hyperparathyroidism

Higher Off-Therapy Relapse Risk with Tenofovir Alafenamide than Entecavir in Non-cirrhotic HBeAg-Negative Chronic Hepatitis B: Insights from End-of-Treatment qHBsAg Stratification. (PubMed, Dig Dis Sci) - "EOT qHBsAg effectively stratifies clinical relapse risk after ETV discontinuation but shows limited discriminative ability after TAF cessation, where relapse rates remain uniformly high across all qHBsAg levels."

Journal • Hepatitis B • Infectious Disease • Inflammation

Drug-Drug Interaction Study Between Hydronidone and Entecavir, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide, and Tenofovir Amibufenamide (clinicaltrials.gov) - P1 | N=64 | Completed | Sponsor: Beijing Continent Pharmaceutical Co, Ltd. | Not yet recruiting ➔ Completed

Trial completion • Fibrosis • Hepatitis B • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis